People · Operator
Named in public records as an officer, director or promoter · active 2012–2024 · Biotechnology, Healthtech, Other Health Care, Other Technology, Biotech / Pharma, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Tempero Bio, Inc. | — | Biotechnology | Series C | $77.0M | $604.5M | 2024 |
| Icebreaker Health, Inc. | — | Healthtech | Series B | $51.5M | $889.3M | 2015 |
| High Plains Physicians, LLC | — | Other Health Care | Series B | $16.8M | $371.7M | 2013 |
| Working Along Your Side Ways Inc | — | Other Technology | Series A | $15.0M | $113.7M | 2021 |
| Next Frontier Biosciences, LLC | — | Biotech / Pharma | Seed | $8.7M | $34.0M | 2014 |
| LotLinx, Inc. | — | Other | Seed | $4.1M | $27.9M | 2014 |
| Redirect Health, LLC | — | Healthtech | Seed | $3.4M | $29.4M | 2018 |
| Cheyenne Surgical Center Llc | — | Other Health Care | Seed | $3.2M | $75.4M | 2012 |
| SISC Doctor Company, LLC | — | Hospitals and Physicians | Seed | $2.3M | $43.1M | 2021 |
| Lumanu, Inc. | — | Other Technology | Seed | $1.8M | $62.2M | 2019 |
Paul Johnson at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Paul Johnson on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michael Martin | 2 | 11 |
| John Romano | 2 | 2 |
| Peter Johnson | 1 | 11 |
| Ketan Patel | 1 | 10 |
| Campbell Murray | 1 | 9 |
| Francisco Gimenez | 1 | 7 |
| David Berg | 1 | 5 |
| Charles Sander | 1 | 3 |
| Thomas Mallon | 1 | 3 |
| Joseph Jimenez | 1 | 3 |
| Jason Knight | 1 | 3 |
| MARK MIOLA | 1 | 2 |
| Marc Graboyes | 1 | 2 |
| Lana Ghanem | 1 | 2 |
| Darryl Baker | 1 | 2 |
| Gerald S. Casilli | 1 | 2 |
| Timothy Dowling | 1 | 2 |
| Leonard V. Short | 1 | 1 |
| Gerald V. Casilli | 1 | 1 |
| Leonard V. Short III | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.